Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia.

Trial Profile

Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2012

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2012 Additional lead trial investigator (Hecht JR) and drug company added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual end date added to 1 Jan 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top